NCT07535658

Brief Summary

The goal of this clinical trial is to learn if photolithographic flat microstructure lenses work to prevent myopia in children. It will also learn about the safety of different designs of photolithographic flat microstructure lenses. The main questions it aims to answer are: Are photolithography flat microstructure lenses effective and safe in preventing myopia in children? Does the depth of tinted lenses affect visual quality? Researchers will compare photolithography flat microstructure lenses to a spectacle lenses with aspherical lenslets to see if photolithography flat microstructure lenses works to prevent myopia in children. Participants will: Wear photolithography flat microstructure lenses or Spectacle Lenses with Aspherical Lenslets more than 8H per day for 1 year. Visit the clinic once every 3 months for checkups and tests.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
255

participants targeted

Target at P75+ for not_applicable

Timeline
20mo left

Started Apr 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Apr 2026Dec 2027

First Submitted

Initial submission to the registry

April 1, 2026

Completed
14 days until next milestone

Study Start

First participant enrolled

April 15, 2026

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 17, 2026

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

April 17, 2026

Status Verified

April 1, 2026

Enrollment Period

1.5 years

First QC Date

April 1, 2026

Last Update Submit

April 14, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Use 1% cyclopentolate hydrochloride eye drops (Cyclogyl) for cycloplegia and compare the difference in Sphere equivalent refractive changes over 12 months.

    Computerized refractometer testing, The formula for calculating sphere equivalent power: sphere power + 0.5 \* cylinder power

    From enrollment to the end of treatment at 12 month

Secondary Outcomes (1)

  • Difference in 12-month axial length (AL, mm) from baseline

    From enrollment to the end of treatment at 12 month

Study Arms (5)

PPML(multi-point defocus design, non-fading, Nuo Tong)

EXPERIMENTAL

The group wears photolithography plano microstructure lenses (PPML) with a multi-point defocus design, manufactured by Nuo Tong, which feature a non-fading optical property.

Device: wearing photolithography plano microstructure lenses with multi-point defocus design, non-fading optical property

PPML (multi-point defocus design, color, light transmittance 55% after photochromism, Nuo Tong)

EXPERIMENTAL

PPML (Photolithography Plano Microstructure Lenses) incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 55% post-activation.

Device: wearing Photolithography Plano Microstructure Lenses incorporates a multi-point defocus optical architecture , featuring photochromic properties with a light transmittance of 55% post-activation

PPML (multi-point defocus design, color, light transmittance 35% after photochromism, Nuo Tong)

EXPERIMENTAL

PPML (Photolithography Plano Microstructure Lenses) incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 35% post-activation.

Device: wearing Photolithography Plano Microstructure Lenses incorporates a multi-point defocus optical architecture , featuring photochromic properties with a light transmittance of 35% post-activation

PPML (designed to reduce contrast, non-fading, Nuo Tong)

EXPERIMENTAL

PPML (Photolithography Plano Microstructure Lenses), designed by Nuo Tong to reduce contrast sensitivity and featuring a non-fading optical property

Device: wearing Photolithography Plano Microstructure Lenses designed to reduce contrast sensitivity and featuring a non-fading optical property

Plano microstructure lenses (multi-point defocus design,Aspherical Lenslets, Essilor Stellest)

ACTIVE COMPARATOR

Plano microstructure lenses featuring multi-point defocus design with aspherical lenslets (Essilor Stellest)

Device: wearing Plano microstructure lenses featuring multi-point defocus design with aspherical lenslets (Essilor Stellest)

Interventions

wearing Photolithography Plano Microstructure Lenses designed by Nuo Tong to reduce contrast sensitivity and featuring a non-fading optical property for more than 8 hours

PPML (designed to reduce contrast, non-fading, Nuo Tong)

Wearing Photolithography Plano Microstructure Lenses incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 55% post-activation for more than 8 hours.

PPML (multi-point defocus design, color, light transmittance 55% after photochromism, Nuo Tong)

Wearing Photolithography Plano Microstructure Lenses incorporates a multi-point defocus optical architecture manufactured by Nuo Tong, featuring photochromic properties with a light transmittance of 35% post-activation for more than 8 hours.

PPML (multi-point defocus design, color, light transmittance 35% after photochromism, Nuo Tong)

wearing photolithography plano microstructure lenses (PPML) with a multi-point defocus design, manufactured by Nuo Tong, which feature a non-fading optical property for more than 8 hours a day.

PPML(multi-point defocus design, non-fading, Nuo Tong)

wearing plano microstructure lenses featuring multi-point defocus design with aspherical lenslets (Essilor Stellest) for more than 8 hours.

Plano microstructure lenses (multi-point defocus design,Aspherical Lenslets, Essilor Stellest)

Eligibility Criteria

Age6 Years - 8 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age: 6 years ≤ age ≤ 8 years (calculated based on the informed consent date);
  • The spherical equivalent (SE) of both eyes is 0D to +1.00D (inclusive of boundary values) after cycloplegia;
  • Astigmatism: Cylindrical power of both eyes ≤ 1.00D;
  • Anisometropia: Difference in spherical equivalent between both eyes ≤ 1.00D;
  • Corrected visual acuity: Best corrected visual acuity (BCVA) of both eyes ≥ 1.0 (decimal notation, 5m);
  • General health status: No systemic syndromes that affect ocular development; no long-term use of growth hormone, corticosteroids, or antiepileptic drugs;
  • Previous intervention: No use of any myopia control methods within the past 3 months, including but not limited to: multifocal glasses, atropine eye drops, red light therapy, acupuncture, etc.
  • Compliance with spectacle wear: Parents ensure that the child wears glasses for ≥8 hours per day;
  • Follow-up capability: Ability to attend scheduled follow-ups for 12 months (4 visits in total);
  • Informed consent from guardian: Legal guardian signs the informed consent form; children also sign the assent form.

You may not qualify if:

  • History or presence of glaucoma, corneal disease, or other ocular organic disease, or acute or chronic ocular inflammation;
  • Combined with systemic major diseases, mental diseases, or systemic collagen metabolism diseases;
  • Used any myopia intervention drugs or devices in the past 3 months;
  • Those who have participated in other similar clinical studies in the past 3 months;
  • Diagnosis of amblyopia, constant strabismus, and other congenital eye diseases;
  • Those who are allergic to the lens material or products related to the study;
  • Allergy to mydriatic agents and related ophthalmic medications;
  • Allergic to photochromic materials or related dyes; taking photosensitizing drugs; suffering from photo-induced skin or neurological disorders;
  • Unable to understand the study content or unable to cooperate with the follow-up;
  • Other reasons why the research doctor believes the patient is not suitable for the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Eye Disease Prevention and treatment Center

Shanghai, 200336, China

Location

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 1, 2026

First Posted

April 17, 2026

Study Start

April 15, 2026

Primary Completion (Estimated)

September 30, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

April 17, 2026

Record last verified: 2026-04

Locations